Hunter-Fleming, Newron deal

Neurology company Newron will acquire Hunter-Fleming for E8 million ($11.6 million) in stock, plus up to E17 million ($25.2 million) in stock milestones. Hunter-Fleming’s lead compound is HF0220, an ...